Drug intelligence / Profile preview

FemLUNA

Development stage: Preclinical
Lead developer: EndoCyclic Therapeutics
Modality: Peptides

Overview

FemLUNA is an investigational imaging agent developed by EndoCyclic Therapeutics for the precise, non-invasive diagnosis of endometriosis. The agent is built upon a proprietary cyclic peptide platform that utilizes cell-permeating, pH-sensitive peptides designed to target diseased tissue specifically. By leveraging selective endocytic pathways, FemLUNA is engineered to identify endometriotic lesions without the use of hormones or radiation, aiming to provide a definitive diagnostic tool that complements the company's therapeutic pipeline, such as ENDO-205.

Brand names: FemLUNA

Beyond the preview

Go deeper on FemLUNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FemLUNA.

Explore the full profile